Understanding the Changing Treatment Landscape of Chronic Rhinosinusitis with Nasal Polyps

CME: 1.0

Target Audience

This activity is designed to meet the educational needs of physicians and other clinicians who treat patients with chronic rhinosinusitis with nasal polyps, including specialists (allergists, immunologists, ENTs) and other health care providers who may treat CRSwNP patients.

Program Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic condition that negatively impacts patients’ quality of life and while CRSwNP pathogenesis is poorly understood, type 2 inflammation has been identified as a major driver for most CRSwNP pathophysiology. Increased understanding has resulted in a new class of medical therapy and targeted biologics to address existing unmet medical needs. As such, it is important for clinicians to understand the rationale behind these new treatments and how best to integrate targeted therapies with existing treatment options.

In this roundtable discussion, expert faculty in CRSwNP offer valuable discussions regarding treatment indications, efficacy, and side effects. Improving learners’ knowledge of type 2 inflammation and immunomodulating therapies as well as improving their competence relating to selection of interventions, individualizing CRSwNP treatments, and optimizing patient outcomes.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify how type 2 inflammation contributes to the pathology of chronic rhinosinusitis with nasal polyps (CRSwNP)
  • Describe the role of immunomodulation for treatment of chronic rhinosinusitis with nasal polyps
  • Assess the role of medications and surgery for the treatments of CRSwNP
  • Individualize CRSwNP treatment based on patient needs and preferences

Post a comment to this article